- Home
- DNLI vs CLVT Comparison
DNLI vs CLVT Comparison
Compare DNLI & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | CLVT |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | DNLI | CLVT |
|---|---|---|
| Price | $16.98 | $3.41 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | ★ $32.58 | $4.50 |
| AVG Volume (30 Days) | 1.7M | ★ 5.6M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,501,200,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,973.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.57 | $3.04 |
| 52 Week High | $24.35 | $5.74 |
Technical Indicators
Market Signals| Indicator | DNLI | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 44.97 |
| Support Level | $16.66 | $3.28 |
| Resistance Level | $17.85 | $3.59 |
| Average True Range (ATR) | 0.80 | 0.17 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 3.07 | 28.26 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.